secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2024-08-16T23:59:59+00:00
Accession:  0001628280-24-037546
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharmaceuticals receives Nasdaq deficiency notice for minimum bid price rule; 180 days to regain compliance
--------------------------------------------------------------------------------

- On Aug 13, 2024, Nasdaq notified X4 that its common stock closing bid price was below $1.00 for 32 consecutive business days.
- Company has until Feb 10, 2025 to regain compliance by closing at $1.00+ for ten consecutive days.
- If not compliant by Feb 10, X4 may be eligible for additional 180-day cure period if it meets other listing standards.
- X4 says it will monitor bid price and consider options including a reverse stock split to cure deficiency.
- There is no immediate delisting; stock continues trading under symbol XFOR on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024037546/0001628280-24-037546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024037546/xfor-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-037546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer